EZZ Life Science Holdings (ASX:EZZ) Debt-to-EBITDA : 0.09 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is EZZ Life Science Holdings Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

EZZ Life Science Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.30 Mil. EZZ Life Science Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.00 Mil. EZZ Life Science Holdings's annualized EBITDA for the quarter that ended in Dec. 2023 was A$3.46 Mil. EZZ Life Science Holdings's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.09.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for EZZ Life Science Holdings's Debt-to-EBITDA or its related term are showing as below:

ASX:EZZ' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.03 Med: 0.06 Max: 0.09
Current: 0.06

During the past 4 years, the highest Debt-to-EBITDA Ratio of EZZ Life Science Holdings was 0.09. The lowest was 0.03. And the median was 0.06.

ASX:EZZ's Debt-to-EBITDA is ranked better than
88.04% of 276 companies
in the Biotechnology industry
Industry Median: 1.34 vs ASX:EZZ: 0.06

EZZ Life Science Holdings Debt-to-EBITDA Historical Data

The historical data trend for EZZ Life Science Holdings's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EZZ Life Science Holdings Debt-to-EBITDA Chart

EZZ Life Science Holdings Annual Data

Trend

Jun20

Jun21

Jun22

Jun23

Debt-to-EBITDA

N/A

0.03

0.06

0.09

EZZ Life Science Holdings Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial			0.08	0.03	0.01	0.07	0.09

Competitive Comparison of EZZ Life Science Holdings's Debt-to-EBITDA

For the Biotechnology subindustry, EZZ Life Science Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

EZZ Life Science Holdings's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EZZ Life Science Holdings's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where EZZ Life Science Holdings's Debt-to-EBITDA falls into.

EZZ Life Science Holdings Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

EZZ Life Science Holdings's Debt-to-EBITDA for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.355	+	0.124)	/	5.093
	=	0.09

EZZ Life Science Holdings's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.304	+	0)	/	3.464
	=	0.09

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.

EZZ Life Science Holdings (ASX:EZZ) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

EZZ Life Science Holdings Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of EZZ Life Science Holdings's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

EZZ Life Science Holdings (ASX:EZZ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EZZ Life Science Holdings Ltd (ASX:EZZ) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

104 Derby Street, Silverwater, NSW, AUS, 2128

Website

https://www.ezzlife.com.au

EZZ Life Science Holdings Ltd is a genomic life science company with a mission to improve quality of life and human health. EZZ has a focus on genomic research and development to address four key human health challenges: genetic longevity, human papillomavirus (HPV), helicobacter pylori, and weight management. The company is engaged in formulation, production, marketing and sale of the EZZ branded health and wellbeing products to retailers and consumers domestically and internationally, and wholesale distribution of the EAORON branded skin care products to retailers in Australia and New Zealand.

EZZ Life Science Holdings (ASX:EZZ) Headlines

No Headlines